| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 7.00 | 12.5% |
| Total Income | 7.00 | 12.5% |
| Expenditure | 141.00 | 8.5% |
| PBT | -128.00 | 14.3% |
| Net Profit | -128.00 | 14.3% |
| OPM | — | |
| NPM | — | |
| EPS | -1.02 | 10.5% |
Arcus Biosciences Reports Q1 2026 Financial Results
06 May 2026 · 6 May, 1:44 am
Summary
Arcus Biosciences reported its financial results for the first quarter ended March 31, 2026. The company had $876 million in cash, cash equivalents, and marketable securities at quarter-end, providing a cash runway until at least the second half of 2028. Revenues for the quarter were $17 million, compared to $28 million for the same period in 2025, with full-year 2026 revenue expected to be between $50 million and $65 million. The net loss for the quarter was $128 million, compared to $112 million for the same period in 2025.
Key Highlights
- 1
Arcus Biosciences reported having $876 million in cash, cash equivalents, and marketable securities at the end of the first quarter of 2026.
- 2
The company believes its cash runway will last until at least the second half of 2028.
- 3
Revenues were $17 million for the first quarter of 2026, compared to $28 million for the same period in 2025.
- 4
Arcus expects to recognize GAAP revenue of between $50 million and $65 million for the full year 2026.
- 5
Net loss was $128 million for the first quarter of 2026, compared to $112 million for the same period in 2025.
- 6
Arcus is focused on completing enrollment for PEAK-1 and initiating a Phase 3 study in the 1L setting by year-end 2026.
Management Comments
Terry Rosen
Ph.D.
"Arcus is entering a new era, with a clear path for casdatifan to be both first and best in the first-line setting, and a portfolio of wholly owned molecules for inflammation and immunology that provide a new strategic optionality as they move into and through development." "Our highest priority is to establish casdatifan as a foundational standard of care in kidney cancer so that patients have the opportunity to benefit from casdatifan-based regimens across lines of treatment.”
Informational and educational content only. Not investment advice.